Comparing the effects of dexmedetomidine and dexamethasone as perineural adjuvants on peripheral nerve block
A PRISMA-compliant systematic review and meta-analysis
Chang Xiong, MM\textsuperscript{a,1*}, Cheng-peng Han, MM\textsuperscript{b}, Dong Zhao, BM\textsuperscript{a}, Zhi-hao Tang, BM\textsuperscript{a}, Yu-fan Zhang, BM\textsuperscript{a}, Jian Wang, MM\textsuperscript{a}

Abstract
Background: Dexmedetomidine (Dexm), a selective alpha-2 adrenoceptor agonist, and dexamethasone (Dexa), a very potent and highly selective glucocorticoid, have both been proven effectively to prolong the duration of local anesthetics (LA) in regional anesthesia. However, data comparing the efficacy of Dexm and Dexa as perineural adjuvants are inconsistent. Therefore, this systematic review and meta-analysis of randomized and quasi-randomized controlled trials (RCTs) was conducted to compare the effects of Dexm and Dexa when used as LA adjuvants on peripheral nerve block (PNB).

Methods: We systematically searched PubMed, Cochrane Library, EMBASE, Web of Science, and ScienceDirect databases up to October, 2020. The primary outcome was the duration of analgesia. Secondary outcomes included incidence of rescue analgesia, cumulative opioid consumption, time required for onset of sensory and motor blockades, duration of sensory and motor blockades, incidence of postoperative nausea and vomiting (PONV), and side effect-associated outcomes (e.g., bradycardia, sedation, hypotension, rates of infection, and neurological complications). The study was registered on PROSPERO, number CRD42020188796.

Results: After screening of full-text relevant articles, 13 RCTs that met the inclusion criteria were retrieved for this systematic review. It was revealed that perineural Dexm provided equivalent analgesic duration to perineural Dexa. Besides, the intake of Dexm increased the incidence of rescue analgesia in limbs surgery, as well as the cumulative opioid consumption, and decreased the time required for onset of sensory and motor blockades for long-acting LA (all \(P < .05\)). Other analysis revealed insignificant difference between the 2 groups in terms of the incidence of PONV (\(P > .05\)). Additionally, 2 studies demonstrated that Dexm possesses more sedative properties than Dexa (\(P < .05\)).

Conclusions: This meta-analysis indicated that the analgesic duration of Dexm and Dexa as LA adjuvants in PNB is the same. Meanwhile, the effects of perineural Dexm and Dexa on some secondary outcomes, including the incidence of rescue analgesia, cumulative opioid consumption, and time required for onset of sensory and motor blockades, are associated with the surgical site and type of LA.

Abbreviations: Dexa = dexamethasone, Dexm = dexmedetomidine, LA = local anesthetics, PNB = peripheral nerve block, PONV = postoperative nausea and vomiting, RCTs = randomized controlled trials.

Keywords: anesthesia adjuvants, dexamethasone, dexmedetomidine, meta-analysis, nerve block, postoperative pain, systematic review
1. Introduction

Poor postoperative pain control may produce a series of detrimental acute and chronic effects on the body.1,11 Compared with intravenous analgesia, regional anesthesia techniques not only provide excellent analgesia effects, but also possess fewer side effects. Peripheral nerve block (PNB) is currently one of the most commonly used regional anesthesia methods. Whether used alone or in combination with general anesthesia, it can accelerate postoperative analgesia.2,3 However, regarding the currently available local anesthetics (LA) for PNB, the duration of postoperative analgesia is a main challenge, and its effect often fades before the peak of postoperative pain.4

Addition of adjuvants including dexametomidine (Dexm),5 dexamethasone (Dexa),6 clonidine,7 buprenorphine,8 magnesium,9 and midazolam10 to LA for regional anesthesia effectively prolongs the postoperative analgesia. Compared with commonly used continuous catheter-based nerve block, adjuvants in LA can reduce multiple postoperative complications.11–13 To date, studies have shown that Dexm and Dexa are the 2 most frequently used adjuvants for LA. They can significantly prolong postoperative analgesic duration, reduce intake of opioids, and their use is associated with a limited number of side effects.11–15 However, there are conflicting reports regarding the overall efficacy of the 2 additives as adjuvants in LA.16–18

Motivated by this controversy, this systematic review and meta-analysis aimed to assess the comparative analgesic efficacy of Dexm and Dexa to light. The primary outcome of this meta-analysis was the duration of analgesia.

2. Materials and methods

2.1. Registration and protocol

Ethical approval and patient consent are not required because this is a systematic review and meta-analysis of previously published studies. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)19 recommendations were followed in the preparation of this review. The protocol of this study was registered at International Prospective Register of Systematic Reviews (PROSPERO) (number CRD42020188796).

2.2. Search strategy

Two independent researchers (Chang Xiong and Cheng-peng Han) conducted the search process in PubMed, Cochrane Library, EMBASE, Web of Science, and ScienceDirect databases from inception of each database to October 2020. The key search terminology was MeSH and its synonyms were “dexametomidine,” “dexamethasone,” and “regional anesthesia/peripheral nerve block/peripheral block.” After filtering titles and abstracts, 13 relevant randomized and quasi-randomized controlled trials (RCTs) were retrieved for analysis. Potentially eligible trials were also manually searched. The retrieval strategy in PubMed database is shown in Supplementary Appendix S1, http://links.lww.com/MD/G380.

2.3. Selection criteria/eligibility

The inclusion criteria were as follows: (a) Intervention: perineural administration of Dexm (combined with LA) (Dexm group); (b) Control: perineural administration of Dexa (combined with LA) (Dexa group); (c) Population: adult patients (subjects who aged ≥18 years old) who underwent surgery with regional anesthesia; (d) Design: RCTs.

2.4. Data extraction

Relevant data, including the authors’ full name, year of publication, the first author’s country of residence, number of patients in each group, type of PNB, adjuvant, type and dose of LA, anesthesia and surgery, postoperative analgesia, and outcomes were extracted independently from eligible articles by 2 researchers.

Primary outcome was the duration of analgesia. Secondary outcomes included the incidence of rescue analgesia, cumulative opioid consumption, blockade-associated outcomes, such as time required for the onset of sensory and motor blockades, the corresponding duration of sensory and motor blockades, incidence of postoperative nausea and vomiting (PONV), and side effect-associated outcomes (e.g., bradycardia, sedation, hypotension, rates of infection, and neurological complications).

Opioid intake was equated into probable morphine consumption [morphine (10 mg) = tramadol (100 mg) = fentanyl (0.1 mg) = pethidine (75 mg) = diclofenac (140 mg), i.v.].20,21

Attempts were made to retrieve raw data for continuous variables from the eligible articles if variables in the full texts were presented as median and range; however, if data could not be extracted, then, the median and range were transformed to the mean ± standard deviation (SD).22 Any disagreements arising from the entire process were arbitrated by a third experienced researcher (Dong Zhao).

2.5. Assessment of risk of bias

Risk of bias was assessed by 2 independent researchers (Chang Xiong and Cheng-peng Han) using the Cochrane Collaboration Risk of Bias tool.23 Any disagreement was also arbitrated by a third researcher (Dong Zhao). The articles were evaluated under 6 bias-based parameters, including selection (random sequence generation and allocation concealment), performance (blinding of participants and personnel), detection (blinding of outcome assessment), attrition (incomplete outcome data), and reporting (selective reporting) bias. The risk of bias for each parameter was classified as “low,” “unclear” or “high.” The Egger test, as well as visual examination of the funnel plot were used to assess potential publication bias; besides, Duval & Tweedie’s trim-and-fill analysis was employed to adjust the effect size accordingly when P-values of Egger test was <.1.

2.6. Statistical analysis

Continuous data on outcomes, including the duration of analgesia, time required for the onset of sensory and motor blockades, the corresponding duration of sensory and motor blockades, and cumulative opioid consumption were presented as mean difference (MD) at 95% confidence interval (CI). The dichotomous data on outcomes, such as incidence of rescue analgesia and PONV were expressed as the relative risk (RR) at 95% CI. The χ² test and I² statistic were employed to estimate statistical heterogeneity across studies. The I² statistic was stratified into 3 levels: low-level (0%–49%), moderate-level (50%–74%), and high-level (>75%). The fixed-effects model
was used in the event of low-level heterogeneity; otherwise, a random-effect model was applied. For moderate-level and high-level of heterogeneity ($I^2 > 50\%$), subgroup analysis was planned based on the following priori hypotheses. RevMan (version 5.3; Cochrane Library, Oxford, UK) was used to perform meta-analyses, and STATA 14/MP (StataCorp., College Station, TX, USA) was used for conducting Egger’s test (metabias module) and Duval & Tweedie’s trim-and-fill analysis (metatrim module).

2.7. Priori hypotheses to explain heterogeneity subgroup analysis

The pre-identified hypotheses used to evaluate heterogeneity is that the effects of Dexm or Dext on PNB depend on surgical site and the type of LA utilized. Specifically, all trials were divided into 2 subgroups according to the surgical site (limbs and thoracic surgeries), and 3 subgroups according to the type of LA (long-acting LA, intermediate + long-acting LA, and intermediate LA).

3. Results of the meta-analysis for outcomes

3.1. Characteristics of the included studies

Five hundred forty seven studies were identified during our first search, among which 83 duplicates were removed after assessment. Through thorough review of the titles, abstracts, and full texts, 13 RCTs were eventually selected for the final analysis. The flowchart of the study selection is shown in Fig. 1. The selected studies were published between 2014 and 2020, and were carried out in different countries, such as India, China, Iran, Korea, Spain, and Chile. The surgeries that were documented in the studies included limbs surgery
Table 1
Characteristics of 13 included studies.

| Study          | Country | Group (N) | Type of peripheral nerve blockade | Local anesthetics | Adjuvant | Type of surgery | Anesthesia | Postoperative analgesia | Outcomes                                                                 |
|----------------|---------|-----------|-----------------------------------|-------------------|----------|----------------|------------|-------------------------|--------------------------------------------------------------------------|
| Aliste J 2019 | Chile   | Dexm vs Dexa (56/53) | Ultrasound-guided infradeltoid block | 1% lidocaine + 0.25% bupivacaine 35 ml | Dexm: 100 μg Dexa: 5 mg | Upper limb surgery | Nerve blockade | None | Duration of analgesia, duration of sensory and motor blockades |
| Gao Z 2019    | China   | Dexm vs Dexa (30/30) | Ultrasound-guided infraclavicular block | 0.5% ropivacaine 30 ml | Dexm: 1 μg/kg Dexa: 10 mg | Upper limb surgery | Video-assisted thoracoscopic lobectomy surgery | General anaesthesia | Duration of analgesia, incidence of rescue analgesia, duration of sensory blockade, postoperative nausea and vomiting |
| Kataria S 2019| India   | Dexm vs Dexa (30/30) | Ultrasonic guided interscalene block | 0.5% ropivacaine 20 ml | Dexm: 0.5 μg/kg (2 mL) Dexa: 8 mg (2 mL) | Upper limb surgery | Nerve blockade | Duration of analgesia, incidence of rescue analgesia, duration of sensory blockade, postoperative nausea and vomiting |
| Kaur M 2018   | India   | Dexm vs Dexa (50/50) | Peripheral nerve stimulator guided suprascapular BPB | 20 ml 2% lidocaine + 18 mL 0.5% bupivacaine | Dexm: 50 μg Dexa: 8 mg (2 mL) | Upper limb surgery | Nerve blockade | None | Duration of analgesia, time required for onset time of sensory and motor blockades, duration of sensory and motor blockades |
| Kumar AN 2014 | India   | Dexm vs Dexa (30/30) | Interscalene BPB | 40 mL 0.25% bupivacaine | Dexm: 50 μg (1 mL) Dexa: 8 mg (1 mL) | Upper limb surgery | Nerve blockade | Duration of analgesia, opioid consumption over 24h after surgery, time required for onset time of sensory and motor blockades, duration of motor blockade, postoperative nausea and vomiting |
| Lee MJ 2016   | Korea   | Dexm vs Dexa (17/17) | Ultrasound-guided axillary BPB | 0.5% ropivacaine 20 mL | Dexm: 100 μg (2 mL) Dexa: 10 mg (2 mL) | Forearm and hand surgery | Nerve blockade | None | Duration of analgesia, time required for onset time of sensory blockade, duration of sensory blockade, incidence of rescue analgesia, opioid consumption over 24h after surgery |
| Ortíz-Gómez JR 2017 | Spain  | FNB+Dexm vs FNB+Dexa (80/81) | Ultrasound-guided FNB and ACB | 0.375% levobupivacaine 20 ml in FNB and 30 mL in ACB | Dexm: 100 μg (1 mL) Dexa: 4 mg (1 mL) | Knee surgery | Spinal anaesthesia | Paracetamol 1g IV, morphine up to 6 mg | Incidence of rescue analgesia, opioid consumption over 24h after surgery |
| Shenker M 2020 | India   | Dexm vs Dexa (48/48) | Ultrasound-guided interscalene BPB | 15 mL 0.2% ropivacaine | Dexm: 1 μg/kg Dexa: 100 μg/kg | Arthroscopic shoulder surgery | General anaesthesia | None | Duration of analgesia, time required for onset time of sensory and motor blockades, duration of sensory and motor blockades |
| Siamak Y 2019 | Iran    | Dexm vs Dexa (26/29) | Ultrasound-guided infradeltoid BPB | 2% lidocaine 28 mL | Dexm: 1 μg/kg Dexa: 8 mg (2 mL) | Forearm surgery | Nerve blockade | Pethidine 25 mg IV if VAS > 4 | Duration of analgesia, incidence of rescue analgesia, opioid consumption over 24h after surgery, time required for onset time of sensory and motor blockades, duration of sensory blockade, postoperative nausea and vomiting |
| Singh N 2020 | India   | Dexm vs Dexa (20/20) | Ultrasound-guided suprascapular BPB | 0.5% ropivacaine 30 mL | Dexm: 1 μg/kg Dexa: 8 mg | Upper limb surgery | Nerve blockade | Tramadol 50 mg IV if VAS ≥ 4 | Duration of analgesia, opioid consumption over 24h after surgery, time required for onset time of sensory and motor blockades, duration of sensory and motor blockades |

(continued)
Surgeries in 9 studies involved the use of long-acting LA, such as ropivacaine, bupivacaine, and levobupivacaine. Three trials reviewed herein used intermediate + long-acting LA, namely lidocaine + bupivacaine. In one study, lidocaine was used for an intermediate-acting LA. The dose of Dexm ranged from 20 to 100 mg or 0.5 to 1 mg/kg, whereas that of Dexa ranged from 4 to 10 mg. Another study reported the use of 2 different trials, thus each experiment was analyzed separately in the meta-analysis, presented as Ortiz-Gómez JR 2017(a) and Ortiz-Gómez JR 2017(b).

Table 1

| Study               | Group (N) | Type of peripheral nerve block   | Local anesthetics                       | Adjuvant                                      | Type of surgery                      | Anesthesia                        | Postoperative analgesia |
|---------------------|-----------|----------------------------------|-----------------------------------------|-----------------------------------------------|-------------------------------------|-----------------------------------|------------------------|
| Niranjan KV 2016    | (50/50)   | Supraclavicular BPB              | 0.5% ropivacaine 30 mL                  | Dexm: 50 mg (2 mL)                            | Upper limb surgeries               | General anesthesia              | IV-PCA (100 mL)         |
| Vinisha A 2020      | (30/30)   | Supraclavicular BPB              | 2% lidocaine + 0.5% bupivacaine         | Dexm: 20 mg (2 mL)                            | Upper limb surgeries               | General anesthesia              | IV-PCA (100 mL)         |
| Zhang P 2019        | (20/20)   | Intercostal nerve block          | 0.5% ropivacaine 28 mL                  | Dexm: 1 mg/kg (2 mL)                          | Thoracoscopic pneumonectomy        | General anesthesia              | IV-PCA (100 mL)         |

3.2. Assessment of risk of bias within studies

Low risk of bias was found in 4 studies. Three studies displayed high risk of bias arising from selection, performance, detection, and attrition. The remaining 6 articles had unclear risks of bias. The outcomes of risk assessment are presented in Fig. 2.
3.3. Duration of analgesia

The duration of analgesia was reported in 11 of the 13 included trials\(^\text{[13–15,17,18,24,25,27–30]}\) (n = 772 patients, of whom 388 received Dexm), and it was defined as the time required to administer the first analgesic supplement post-operatively. The random-effects model used in eleven studies showed that the MD between Dexm and Dext was 15.7 minutes (95% CI: -52.05 to 83.45; P = .65; Figs. 3 and 4). However, regarding a great degree of heterogeneity
(I² = 97%), we attempted to use the priori subgroup hypotheses to perform analysis. For the subgroup of surgical site, the pooled effect of limbs surgery or thoracic surgery demonstrated that Dexm and Dexa have similar analgesic durations (P = .63 and I² = 0 for subgroup differences). For the subgroup of various types of LA, the pooled effect of long, intermediate + long or intermediate-acting LA indicated that Dexm had an equivalent analgesic duration with Dexa (P = .75 and I² = 0 for subgroup differences). The data that compared peripheral Dexa and Dexm used in a surgical site at the limbs and thoracic surgeries, as well as mixed with different types of LA for long, intermediate + long, and intermediate-acting LA showed no significant difference in analgesic duration (Figs. 3 and 4). The findings of the sensitivity analysis did not significantly vary from these summarized results.

### 3.4. Incidence of rescue analgesia

Four trials[14,16,18,26] assessed incidence of rescue analgesia (one study[26] included 2 different trials). The synthetic analysis performed by using a random-effect model revealed a higher

![Figure 5](image-url) Forest plot (subgroup analysis of surgical site) comparing the effect of Dexm and Dexa on incidence of rescue analgesia.

![Figure 6](image-url) Forest plot (subgroup of various types of LA) comparing the effect of Dexm and Dexa on incidence of rescue analgesia; LA = local anesthetics.
incidence of rescue analgesia in the Dexm group compared with that in the Dexa group (RR: 1.37, 95% CI: 0.88–2.15, \( I^2 = 53\%\); \( P = .16\); Figs. 5 and 6), although the difference was not statistically significant. However, subgroup analysis of surgical site showed that in limbs surgery, the incidence of rescue analgesia in Dexm group was 1.51 times higher than that in Dexa group (\( P < .05\)), while there was no significant difference in thoracic surgery (Fig. 5). In addition, subgroup analysis of LA demonstrated that perineural Dexm increased the incidence of rescue analgesia for long-acting LA compared with Dexa, whereas no significant difference was noted in intermediate-acting LA between the 2 groups (Fig. 6).

3.5. Opioid consumption 24hours after surgery

Six studies\(^{[13–15,25,26,28]}\) reported 24-hours cumulative opioid intake (morphine equivalents) postoperation. Pooled results demonstrated that there was no significant increase in morphine intake in this period (24-hours) in individuals put on Dexm compared with those on Dexa (MD = 0.53; 95% CI: −0.01 to 1.07; \( I^2 = 64\%\); \( P = .05\); Figs. 7 and 8). Subgroup analysis revealed that compared with perineural Dexa, Dexm increased cumulative opioid consumption only in limbs surgery (MD = 0.65; 95% CI: 0.04–1.27; \( I^2 = 67\%\); \( P = .04\); Fig. 7), whereas no significant difference was found in other subgroups (thoracic surgery and long/intermediate-acting LA) (Figs. 7 and 8).
3.6. Time required for the onset of sensory and motor blockades

Time required for onset of sensory and motor blockades was reported in 8\(^\text{13,14,16,24,27-30}\) and 8\(^\text{13,14,24,27-30}\) studies, respectively. The pooled analysis indicated that onset time of sensory blockade was decreased by 1.1 minutes (95% CI: -2.14 to -0.05, \(I^2 = 87\%\); \(P = .04\)) with Dexm intake compared with Dexa intake (Fig. 9), and there was no significant difference in onset time of motor blockade between intake of Dexa and Dexm (Fig. 10). Subgroup analysis showed that Dexm had a greater facilitative effect.
on long-acting LA. Compared with Dexa, Dexm shortened the time required for the onset of sensory blockade by 2.24 minutes (95% CI: −4.09 to −0.39) and that of the motor blockade by 2.18 minutes (95% CI: −3.96 to −0.4) for long-acting LA (Figs. 9 and 10).

3.7. Duration of sensory and motor blockades

Nine[14,16,17,24,25,27–30] and 8[14,17,24,25,27–30] studies reported the durations of sensory and motor blockades, respectively. Random-effects model did not reveal any significant differences in the duration of sensory blockade (MD: 27.73; 95% CI: −59.66 to 115.11; I² = 97%; P = .53; Fig. 11) between the 2 groups, while it was revealed that Dexm prolonged the duration of motor blockade by 82.6 minutes (95% CI: 15.95 to 149.24; I² = 97%; P = .02) more than Dexa (Fig. 12). However, subgroup analysis showed that Dexm combined with intermediate-acting LA prolonged the duration of sensory blockade, which was longer than that of Dexa, whereas this result was not observed in long-acting or intermediate + long-acting LA (Fig. 11). Besides, it was revealed that in various types of LA, the 2 additives did not have a significant influence on the duration of motor blockade, which is different from the estimated overall effects (Fig. 12).

3.8. Incidence of postoperative nausea and vomiting

Four trials[13–15,18] investigated the incidence of PONV. The pooled analysis revealed that there was no significant difference between the 2 groups (RR: 0.44; 95% CI: 0.15–1.35; I² = 0; P = .15; Fig. 13), with no heterogeneity.

3.9. Publication bias

No substantial asymmetry was detected by visual examination of the funnel plot (Fig. 14). There was no evidence of publication bias for these outcomes among included trails except the Egger test for duration of motor blockades (P < .1). Thus, we performed a Duval & Tweedie’s trim-and-fill analysis, which demonstrated that the effect size was not changed. The Egger test for clinical outcomes was displayed in Table 2.

3.10. Complications

A previous study[13] reported blockade-associated complications, including Horner’s syndrome and dysphonia. Two studies[17,27] demonstrated that Dexm displayed more sedative properties than Dexa (P < .05). Other complications, such as bradycardia and hypotension, were also reported, while their incidence was low, with no significant difference between the 2 groups.

4. Discussion

To our knowledge, this is a pioneering systematic review and meta-analysis aiming to directly assess the comparative efficacies of Dexm and Dexa when they were separately utilized as adjuvants for PNB. This meta-analysis incorporated 13 RCTs encompassing 1126 patients. We found that there was no significant difference in duration of analgesia and incidence of PONV between Dexm and Dexa groups. Meanwhile, intake of Dexm increased the incidence of rescue analgesia in limbs surgery, as well as the cumulative opioid consumption, and shortened the time required for onset of sensory and motor blockades for long-acting LA, which indicated that the effects of the 2 adjuvants on PNB were interfered by the nature of pain and type of LA. Specifically, Dexa may be better in postoperative pain management, while Dexm possesses a number of advantages in terms of shortening the time required for onset of sensory and motor blockades. All the trials included in this meta-analysis did
not report serious adverse effects of the 2 adjuvants. For Dexm, the postoperative sedation may be more efficacious than that of Dexa, which is also acceptable. In addition, the clinical meaningfulness of our results may be restricted in virtue of the high degree of heterogeneity found in the included trials, although we had used prior hypotheses to explain them.

Incorporation of adjuvants in LA has significantly attracted scholars’ attention owing to their contribution in managing postoperative pain. Adjutants enhance the pain-relieving effect of analgesics, with relatively few side-effects. The first adjuvant was introduced in 1982, and since then, several other armamentariums (e.g., midazolam, buprenorphine, ketamine, clonidine, magnesium, epinephrine, Dexm, Dexa, etc.) have been discovered.[31–33] At present, Dexm and Dexa are the 2 most widely used additives in LA, however, their comparative advantages remain inconsistent. A recent meta-analysis suggested that Dexa may be a better adjuvant than Dexm in supraclavicular brachial plexus block,[34] because it significantly prolongs the duration of analgesia. The results of the present meta-analysis were slightly dissimilar to those findings, in the sense that, we found the duration of analgesia associated with Dexm was longer than that of Dexa, although the difference was not statistically significant. This discrepancy may be explained by the indirect comparison employed in a previous meta-analysis,[34] and as mentioned by the authors of the above meta-analysis, a head-to-head comparison is essential to effectively assess the efficacy of Dexm and Dexa.

To date, the precise mechanism with which dexmedetomidine and dexamethasone prolong the duration of nerve blocks is not fully understood, but it is thought to be multifactorial. One of the ways in which adjuvants mediate the aforementioned function is by increasing vasoconstriction of the surrounding blood vessels.[35,36] Dexmedetomidine, in particular, is thought to bind on locus ceruleus, thus interfering with norepinephrine release from the respective cells.[37] Dexamethasone on its part impairs inflammation[38] and transmission of sensory signals in unmy-
eliminated C-fiber cells. As far as these mechanisms are currently mastered, it has not been discovered that they can cause serious adverse consequences, especially whether this “off-label” method of perineural administration will cause potential neurological complications. In recent years, multiple studies from human and animal experiments have demonstrated the safety of both dexmedetomidine and dexamethasone as adjuvants in local anesthetics. And in this review, except for dexmedetomidine-related bradycardia and a slightly higher degree of sedation, no other serious adverse reactions were found.

It is noteworthy that Dexm significantly reduces the time required for onset of sensory and motor blockades for long-acting LA. However, addition of both Dexm and Dexa to LA can shorten the time required for onset of the sensory and motor blockades compared with LA alone, while this feature is not altered by the type of LA (intermediate-acting or long-acting). Thus, we hypothesized that Dexm and Dexa have either 2 pathways of action or a same pathway of action, whereas Dexm has a stronger effect, which is amplified in long-acting LA. In the current meta-analysis, we also found that the quality of postoperative analgesia (incidence of rescue analgesia and cumulative opioid consumption) using Dexm in limbs surgery is worse than that of Dexa; however, in thoracic surgery, the effects of the 2 additives are equivalent. This finding is consistent with result of a previous research, in which Dexm provides superior postoperative analgesia in more painful surgeries.

| Table 2 |
| --- |
| Publication bias on the association of each clinical outcome. |
| **Duration of analgesia** | **Incidence of rescue analgesia** | **Opioid consumption over 24h after surgery** | **Time required for onset time of sensory blockade** | **Time required for onset time of motor blockade** | **Duration of sensory blockade** | **Duration of motor blockade** |
| Egger test (P) | 0.517 | 0.265 | 0.301 | 0.299 | 0.752 | 0.115 | 0.071 |
Hence, further exploration of these mechanisms is warranted, and the difference between the 2 adjuvants in more types of surgery or pain should be studied as well.

Regarding limitations of the current meta-analysis, firstly, a limited number of reports were included herein and there was a high degree of clinical heterogeneity between included studies, which may increase the variability of outcomes and restrict the generalizability of our results. Second, this study was only based on 2 surgical sites and more types of surgery should be studied in future researches. Furthermore, it may be more meaningful to analyze the specificity of Dexm and Dexa.

To sum up, when choosing a perineural adjuvant for PNB, the results of this meta-analysis recommend that for limbs surgery, Dexm is preferred when involving long-acting LA. For thoracic surgery or pain should be studied as well. Hence, further exploration of these mechanisms is warranted, and the difference between the 2 adjuvants in more types of surgery or pain should be studied as well.

Acknowledgments
We thank TopEdit (www.topeditsci.com) for its linguistic assistance during the preparation of this manuscript.

Author contributions
Conceptualization: Cheng-Peng Han.
Data curation: Cheng-Peng Han, Zhi-Hao Tang.
Formal analysis: Chang Xiong, Cheng-Peng Han, Dong Zhao.
Investigation: Chang Xiong, Cheng-Peng Han, Dong Zhao.
Methodology: Chang Xiong, Cheng-Peng Han, Dong Zhao, Yu-Fan Zhang.
Project administration: Jian Wang.
Resources: Yu-Fan Zhang.
Software: Chang Xiong, Cheng-Peng Han, Zhi-Hao Tang, Yu-Fan Zhang.
Validation: Zhi-Hao Tang, Jian Wang.
Writing – original draft: Chang Xiong.
Writing – review & editing: Chang Xiong.

References
[1] Small C, Laycock H. Acute postoperative pain management. Br J Surg 2020;107:a70–80.
[2] Liu SS. The effect of analgesic technique on postoperative patient-reported outcomes including analgesia: a systematic review. Anesth Analg 2007;105:789–808.
[3] McCartney CJ, Brull R, Chan VW, et al. Early but no long-term benefit of regional compared with general anesthesia for ambulatory hand surgery. Anesthesiology 2004;101:461–7.
[4] Gramke HF, de Rijke JM, van Kleef M, et al. The prevalence of postoperative pain in a cross-sectional group of patients after day-case surgery in a university hospital. Clin J Pain 2007;23:543–8.
[5] Marhofer D, Kettner SC, Marhofer P, Pils S, Weber M, Zeitlinger M. Dexmedetomidine as an adjuvant to ropivacaine prolongs peripheral nerve block: a volunteer study. Br J Anaesth 2013;110:438–42.
[6] Parrington S, O’Donnell DJ, Chan VW, et al. Dexmedetomidine added to mepivacaine prolongs the duration of analgesia after supraclavicular brachial plexus block. Reg Anesth Pain Med 2010;35:422–6.
[7] McCartney CJ, Duggan E, Apatu E. Should we add clonidine to local anaesthetic for peripheral nerve block? A qualitative systematic review of the literature. Reg Anesth Pain Med 2007;32:330–8.
[8] Candido KD. Buprenorphine added to the local anaesthetic for axillary brachial plexus block prolongs postoperative analgesia. Reg Anesth Pain Med 2002;27:162–7.
[9] Buwanendran A, McCarthy RJ, Kroin JS, Leong W, Perry P, Tuman KJ. Intrathecal magnesium prolongs fentanyl analgesia: a prospective, randomized, controlled trial. Anesth Analg 2002;95:661–6.
[10] Murali Krishna T, Panda NB, Batra YK, Rajeev S. Combination of low doses of intrathecal ketamine and midazolam with bupivacaine improves postoperative analgesia in orthopaedic surgery. Eur J Anaesthesiol 2008;25:299–306.
[11] Grant SA, Nielsen KC, Greengrass RA, Steele SM, Klein SM. Continuous peripheral nerve block for ambulatory surgery. Reg Anesth Pain Med 2001;26:209–14.
[12] Ilfeld BM. Continuous peripheral nerve blocks: an update of the published evidence and comparison with novel, alternative analgesic modalities. Anesth Analg 2017;124:308–35.
[13] Kataria S, Mitra S, Sarao R, Jindal S, Gupta R. A randomized double blinded trial comparing dexmedetomidine with dexamethasone as an adjunct to ropivacaine in ultrasound guided interscalene block for arthroscopic shoulder surgery. Asian J Anaesthesiol 2019;57:10–8.
[14] Siamak Y, Shahamat H, Alizadeh A, Khezri MB. Comparing postoperative analgesic effect of dexmedetomidine or dexamethasone added to lidocaine through intracavitary block in forearm surgery. Clin J Pain 2019;35:766–71.
[15] Zhang P, Liu S, Zhu J, Rao Z, Liu C. Dexamethasone and dexmedetomidine as adjuvants to local anesthetic mixture in intercostal nerve block for thoracoscopic pneumonectomy: a prospective randomized study. Reg Anesth Pain Med 2019;44:917–22.
[16] Lee MJ, Koo DJ, Choi YS, Lee KC, Kim HY. Dexamethasone or dexmedetomidine as local anesthetic adjuvants for ultrasound-guided axillary brachial plexus blocks with nerve stimulation. Korean J Pain 2016;29:29–33.
[17] Aliste J, Layera S, Bravo D, et al. Randomized comparison between perineural dexamethasone and dexmedetomidine for ultrasound-guided infracavicular block. Reg Anesth Pain Med 2019;44:911–6.
[18] Gao Z, Xiao Y, Wang Q, Li Y. Comparison of dexmedetomidine and dexamethasone as adjuvant for ropivacaine in ultrasound-guided erector spine plane block for video-assisted thoracic surgical lobectomy surgery: a randomized, double-blind, placebo-controlled trial. Ann Transl Med 2019;7:668–77.
[19] Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
[20] Von Korff M, Saunders K, Thomas Ray G, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain 2008;24:521–7.
[21] de Oliveira Filho GR, Kammer RS, Dos Santos HC. Duloxetine for the treatment acute postoperative pain in adult patients: a systematic review with meta-analysis. J Clin Anesth 2020;63:109785.
[22] Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13.
[23] Huggins JPT, Altman DG, Gartusha PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d7928.
[24] Kaur M, Lakhani A, Hashia AM. Comparative study between dexamethasone and dexmedetomidine in supraclavicular block. Int J Adv Med 2018;5:57–61.
[25] Kumar AN. Comparative study between 0.25% bupivacaine with 8 mg dexamethasone and 0.25% bupivacaine with 30 µg dexamethasone as an adjuvant for interscalene brachial plexus block: prospective clinical study. J Evolution Med Dent Sci 2014;3:13111–9.
[26] Ortiz-Gómez JR, Perpérez-Candel M, Vázquez-Torres JM, et al. Postoperative analgesia for elective total knee arthroplasty under
subarachnoid anesthesia with opioids: comparison between epidural, femoral block and adductor canal block techniques (with and without perineural adjuvants). A prospective, randomized, clinical trial. Minerva Anestesiologica 2017;83:50–8.

27. Shekar M, Kanakalakshmi ST, Mathew S, et al. Comparison of ultrasound guided interscalene brachial plexus block using 0.2% ropivacaine with dexmedetomidine and 0.2% ropivacaine with dexmethasone—A prospective observational study. Sri Lankan J Anesthesiol 2020;28:114–8.

28. Singh N, Gupta S, Kathuria S. Dexmedetomidine vs dexamethasone as an adjuvant to 0.5% ropivacaine in ultrasound-guided supraclavicular brachial plexus block. J Anaesthesiol Clin Pharmacol 2020;36:238–43.

29. Niranjan KV, Ashutosh R. A clinical comparison of dexmedetomidine and dexamethasone as adjuvant to ropivacaine in supraclavicular brachial plexus blocks for upper arm surgeries. Int J Adv Res Biol Sci 2016;3:56–61.

30. Vinisha A, Prakash PV, Reddy KM. A comparative study of dexmedetomidine and dexamethasone as adjuvants to local anesthetics in brachial plexus block for upper limb surgeries. Int J Adv Res 2020;8:998–1002.

31. Candido KD, Knezevic NN. All adjuvants to local anesthetics were not created equal: animal data evaluating neurotoxicity, thermal hyperalgesia, and relevance to human application. Reg Anesth Pain Med 2011;36:211–2.

32. Kazemeini A, Rahimi M, Fazeli MS, et al. The effect of local injections of bupivacaine plus ketamine, bupivacaine alone, and placebo on reducing postoperative anal fissure pain: a randomized clinical trial. Scientific World Journal 2014;2014:424152.

33. Buvanendran A, Kroin JS, Li J, Moric M, Tuman KJ. Relative contribution of adjuvants to local anesthetic for prolonging the duration of peripheral nerve blocks in rats. Reg Anesth Pain Med 2016;41:589–92.

34. Albrecht E, Vorobeichik L, Jacot-Guillarmod A, Fournier N, Abdallah FW. Dexmethasone is superior to dexmedetomidine as a perineural adjuvant for supracaclavicular brachial plexus block: systematic review and indirect meta-analysis. Anesth Analg 2019;128:543–54.

35. Marks R, Barlow JW, Funder JW. Steroid-induced vasoconstriction: glucocorticoid antagonist studies. J Clin Endocrinol Metab 1982;54:1075–7.

36. Talke P, Lobo E, Brown R. Systemically administered alpha2-agonist-induced peripheral vasoconstriction in humans. Anesthesiology 2003;99:65–70.

37. Guo TZ, Jiang JY, Buttermann AE, Maze M. Dexmedetomidine injection into the locus ceruleus produces antinociception. Anesthesiology 1996;84:873–81.

38. Bastos LF, Medeiros DC, Vieira RP, Watkins LR, Coelho MM, Moraes MF. Intraneural dexamethasone applied simultaneously to rat sciatic nerve constriction delays the development of hyperalgesia and allodynia. Neurosci Lett 2012;510:20–3.

39. Johansson A, Hao J, Spöld B. Local corticosteroid application blocks transmission in normal nociceptive C-fibres. Acta Anaesthesiol Scand 1990;34:335–8.

40. Baerswyl M, Kirkham KR, Jacot-Guillarmod A, Albrecht E. Efficacy of perineural vs systemic dexamethasone to prolong analgesia after peripheral nerve block: a systematic review and meta-analysis. Br J Anaesth 2017;119:183–91.

41. Vorobeichik L, Brull R, Abdallah FW. Evidence basis for using perineural dexamethasone to enhance the quality of brachial plexus nerve blocks: a systematic review and meta-analysis of randomized controlled trials. Br J Anaesth 2017;118:167–81.

42. Ma R, Wang X, Lu C, et al. Dexamethasone attenuated bupivacaine-induced neuron injury in vitro through a threonine-serine protein kinase B-dependent mechanism. Neuroscience 2010;167:329–42.

43. Trifa M, Tumin D, Tobias JD. Dexmedetomidine as an adjunct for caudal anesthesia and analgesia in children. Minerva Anestesiologica 2018;84:836–47.

44. Brummett CM, Norat MA, Palmisano JM, Lydic R. Perioperative administration of dexmedetomidine in combination with bupivacaine enhances sensory and motor blockade in sciatic nerve block without inducing neurotoxicity in rat. Anesthesiology 2008;109:502–11.

45. Schnabel A, Reichl SU, Weibel S, et al. Efficacy and safety of dexmedetomidine in peripheral nerve blocks: a meta-analysis and trial sequential analysis. Eur J Anaesthesiol 2018;35:745–58.

46. Bindal D, Narang N, Mahindra R, Gupta H, Kuhre J, Saxena A. Effect of dexamethasone on characteristics of supracaclavicular nerve block with bupivacaine and ropivacaine: a prospective, double-blind, randomized control trial. Anesth Essays Res 2018;12:234–9.

47. Schnabel A, Meyer-Friëßem CH, Reichl SU, Zahn PK, Pogatzki-Zahn EM. Is intraoperative dexmedetomidine a new option for postoperative pain treatment? A meta-analysis of randomized controlled trials. Pain 2013;154:1140–9.